B&G Foods vs Utz Brands
BGS and UTZ side by side, both in food and kindred products. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BGS and UTZ compare
Utz Brands is the larger company, worth 6.9 times as much as B&G Foods ($2.1B against $298M).
Utz Brands grew revenue faster over the last twelve months (2.0% versus −4.9% for B&G Foods).
Utz Brands keeps more of each dollar of sales as profit, with a net margin of −2.0% compared with −4.0% at B&G Foods.
Both pay dividends: B&G Foods yields 15.5% and Utz Brands 1.8%.
B&G Foods scores higher on the StockData Score (9 against 5 for Utz Brands), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BGS | UTZ |
|---|---|---|
| Size and price | ||
| Market cap | $298M | $2.1B |
| Share price | $3.67 | $14.28 |
| Change, 1 year | −19.7% | 35.7% |
| Change, 5 years | −88.0% | −7.1% |
| Beta (5Y) | 0.76 | 0.00 |
| Employees | 2,497 | 3,100 |
| StockData Score | ||
| Total score | 9 (better) | 5 |
| Valuation score | 3 (better) | 0 |
| Growth score | 2 (better) | 1 |
| Performance score | 0 | 0 |
| Health score | 1 | 2 (better) |
| Dividend score | 3 (better) | 2 |
| Valuation | ||
| P/S | 0.2× (better) | 1.4× |
| P/B | 0.8× (better) | 3.0× |
| EV/EBITDA | 17.8× (better) | 35.4× |
| P/FCF | 4.7× (better) | 40.2× |
| FCF yield | 21.4% (better) | 2.5% |
| Fair value | $12.88 | $8.14 |
| Margin of safety | 71.5% (better) | −75.4% |
| Growth | ||
| Revenue growth (TTM) | −4.9% | 2.0% (better) |
| Revenue growth, 5Y average | −1.5% | – |
| Net income growth (TTM) | – | −260% |
| EPS growth (TTM) | – | −257% |
| Profitability | ||
| Gross margin | 21.5% | 25.4% (better) |
| Operating margin | 3.6% (better) | 0.67% |
| Net margin | −4.0% | −2.0% (better) |
| FCF margin | 3.6% (better) | 3.5% |
| Return on equity | −15.8% | −4.1% (better) |
| Return on invested capital | 2.1% (better) | 0.51% |
| Financial health | ||
| Debt / equity | 6.38 | 1.21 (better) |
| Net debt / EBITDA | 15.44 | 8.00 (better) |
| Interest coverage | – | 0.2× |
| Current ratio | 1.62 (better) | 1.06 |
| Altman Z-score | 0.97 | 1.21 (better) |
| Piotroski F-score | 5 | 5 |
| Dividends and buybacks | ||
| Dividend yield | 15.5% (better) | 1.8% |
| Years of dividend growth | 0 | – |
| Dividend growth, 5Y average | −16.7% | – |
| Shareholder yield | 15.5% (better) | 1.8% |
| Ownership | ||
| Held by institutions | 57.3% | 53.5% |
| Held by insiders | 5.3% | 43.0% |
| Insider net buying, 12 months | −$248K | $13.6K (better) |
| Short interest, % of float | 18.4% | 6.4% |
Go deeper
- BGS stock overview
- BGS income statement
- BGS valuation and score
- UTZ stock overview
- UTZ income statement
- UTZ valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.